학술논문
No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine—a prospective multicenter study by the Polish Adult Leukemia Group
Document Type
article
Author
Source
Frontiers in Oncology, Vol 14 (2024)
Subject
Language
English
ISSN
2234-943X
Abstract
IntroductionInfections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia